+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial



Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial



Archives of General Psychiatry 64(6): 679-688



Antidepressant treatments that achieve a higher remission rate than those currently available are urgently needed. The thyroid hormone triiodothyronine may potentiate antidepressant effects. To determine the antidepressant efficacy and safety of liothyronine sodium (triiodothyronine) when administered concurrently with the selective serotonin reuptake inhibitor sertraline hydrochloride to patients with major depressive disorder. Double-blind, randomized, 8-week, placebo-controlled trial. Outpatient referral centers. A total of 124 adult outpatients meeting unmodified DSM-IV criteria for major depressive disorder without psychotic features. Patients were randomized to receive sertraline hydrochloride (50 mg/d for 1 week; 100 mg/d thereafter) plus liothyronine sodium (20-25 microg/d for 1 week; 40-50 microg/d thereafter) or sertraline plus placebo for 8 weeks. The primary outcome measure was categorical response to treatment (> or =50% decrease in scores on the 21-item Hamilton Rating Scale for Depression from baseline to study end point). Remission rate (final Hamilton Rating Scale for Depression score, < or =6) was a secondary outcome measure. Intent-to-treat Hamilton Rating Scale for Depression response rates were 70% and 50% in the sertraline-liothyronine and sertraline-placebo groups, respectively (P = .02; odds ratio, 2.93; 95% confidence interval, 1.23-7.35); remission rates were 58% with sertraline-liothyronine and 38% with sertraline-placebo (P = .02; odds ratio, 2.69; 95% confidence interval, 1.16-6.49). Baseline T(3) values were lower in patients treated with sertraline-liothyronine who had remissions than in those without remissions (t(48) = 3.36; P<.002). Among patients treated with sertraline-liothyronine, remission was associated with a significant decrease in serum thyrotropin values (F(1,73) = 4.00; P<.05). There were no significant effects of liothyronine supplementation on frequency of adverse effects. These results demonstrate enhancement of the antidepressant effect of sertraline by concurrent treatment with liothyronine without a significant increase in adverse effects. The antidepressant effect of liothyronine may be directly linked to thyroid function.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052181766

Download citation: RISBibTeXText

PMID: 17548749

DOI: 10.1001/archpsyc.64.6.679


Related references

Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. American Heart Journal 156(3): 437-444, 2008

A randomized double-blind placebo controlled trial of the selective serotonin reuptake inhibitor sertraline for major depression after acute coronary syndromes The SADHART trial. Circulation 104(17 Suppl.): II 344, 2001

P-2-45 The treatment of dysthymia with sertraline: A double-blind placebo-controlled trial in dysthymic outpatients without major depression. European Neuropsychopharmacology 5(3): 289-290, 1995

Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. Journal of Clinical Psychiatry 61(11): 821-827, 2000

A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology 231(5): 939-948, 2014

Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Archives of General Psychiatry 63(5): 521-529, 2006

Nepeta menthoides Boiss. & Buhse freeze-dried aqueous extract versus sertraline in the treatment of major depression: A double blind randomized controlled trial. Complementary Therapies in Medicine 26: 164-170, 2016

Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. American Journal of Psychiatry 157(10): 1686-1689, 2000

The Beyond Ageing Project Phase 2--a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial. Trials 16: 247, 2015

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet. Oncology 8(7): 603-612, 2007

A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. International Clinical Psychopharmacology 9(2): 95, 1994

A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression. European Psychiatry 12(1): 34-41, 1997

Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. International Immunopharmacology 17(3): 917-923, 2013

A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Journal of Clinical Psychiatry 58(11): 484-491, 1997

The effect of sertraline add-on to brief dynamic psychotherapy for the treatment of postpartum depression: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 73(2): 235-241, 2012